查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2028 年缺铁性贫血治疗市场预测——按疗法、治疗领域、年龄、最终用户和地区进行的全球分析
市场调查报告书
商品编码
1273281

2028 年缺铁性贫血治疗市场预测——按疗法、治疗领域、年龄、最终用户和地区进行的全球分析

Iron Deficiency Anemia Therapy Market Forecasts to 2028 - Global Analysis By Therapy, Therapy Area, Age, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC，全球缺铁性贫血 (IDA) 治疗市场将在 2022 年达到 18.7 亿美元，到 2028 年将达到 23.6 亿美元，预计复合年增长率为 3.95%在预测期间。

缺铁性贫血 (IDA) 是当血液中没有足够的健康红细胞时发生的一种病症。 红细胞有助于储存和运输血液中的氧气，由铁製成。 红细胞为人体组织提供氧气。 红细胞含有铁，这是合成血红蛋白所必需的。 如果您没有足够的血红蛋白，您的身体可能无法获得足够的氧气。 水果、肉类、蔬菜和谷物等含铁量高的食物有助于治疗和预防。 服用维生素 C 有助于预防缺铁。

根据 2021 年 11 月发布的《全球营养报告》，印度 15-49 岁的女性中，超过半数，约占人口的 53%，被发现患有贫血。

市场动态：

驱动程序

缺铁性贫血患病率增加

缺铁性贫血 (IDA) 是一个全球性的健康问题。 缺铁性贫血影响不同年龄和性取向的人。 然而，据说十几岁的女孩更容易受到影响。 铁需求增加、每月出血、疾病和虫害可能是罪魁祸首。 不食用富含铁的食物（如肉类）的人更容易患缺铁性贫血。 频繁献血和营养缺乏正在推动对治疗缺铁性贫血 (IDA) 药物的需求。

约束

缺乏足够的测试

贫血可能由多种健康问题引起。 没有足够的测试来诊断这种情况。 贫血往往被低估和治疗不足。 它通常通过铁补充剂进行管理，并记录为单一诊断。 其症状和指标的频率和严重程度各不相同。 如果管理不当，可能会导致心力衰竭和死亡。 这些因素阻碍了市场需求。

机会

癌症发病率增加

癌症患者更容易患上缺铁性贫血。 肺癌和乳腺肿瘤已被证明在实体瘤中贫血的频率最高。 贫血是由多发性骨髓瘤、白血病和淋巴瘤等血癌产生的异常血细胞引起的。 这些疾病会削弱免疫系统。 化疗和放疗等癌症治疗也会加剧癌症患者的贫血。 从这方面来看，市场开闢了更多的可能性。

威胁：

铁补充剂的副作用

摄入含铁药物会产生噁心、呕吐、胃痛、便秘和食慾不振等不良反应。 这些药物还会引起过量症状，例如疲劳、虚弱、呼吸浅或急促、皮肤发青、抽筋、皮肤苍白和指甲苍白。 所有这些不利影响都阻碍了市场的扩张。

COVID-19 的影响：

COVID-19 大流行对医疗保健系统产生了巨大影响，严重影响了感染和未感染 COVID-19 的人，以及停止治疗、管理和确保资源的程序等。 COVID-19 患者贫血的流行导致对铁疗法和其他贫血相关治疗的需求增加。

儿科领域预计将成为预测期内最大的领域

儿科部门估计有良好的增长。 儿童经常缺铁。 缺铁有多种形式，从轻度到缺铁性贫血。 儿童的生长发育可能会受到未经治疗的缺铁症的影响。 儿童缺铁通常由营养缺乏、早产和低出生体重引起。 血红蛋白和血细胞比容诊断结果的改进正在推动这一领域的需求。

在预测期内，预计口服铁製剂的复合年增长率最高。

口服铁补充剂由于恢復铁平衡的能力强，预计在预测期内将以最快的复合年增长率增长。 应使用口服铁补充剂至少 3 至 6 个月，以补充铁储备并使铁蛋白水平正常化。 通过增加体内铁和血红蛋白的含量，它可以缓解患者的症状。 口服铁片含有不同水平的元素铁。

市场份额最高的地区

由于其发达的医疗保健系统，预计在预测期内北美将占据最大的市场份额。 该地区医疗基础设施发达，竞争者少，因此对缺铁性贫血治疗药物的需求不断增加。 此外，消费者对女性健康问题意识的增强和技术的进步正在推动该地区的市场扩张。

复合年增长率最高的地区：

由于人口增长和政府举措，预计亚太地区在预测期内的复合年增长率最高。 这个地区的女性人口非常多。 该地区的市场需求受到医疗保健成本上升、政府支持医疗保健行业的努力以及对 IDA 治疗需求不断增长的推动。

主要发展：

2023 年 2 月，Rockwell Medical, Inc. 宣布与美国最大的专业护理机构透析提供商 Concerto Renal Services（“Concerto”）签订了为期三年的产品采购协议。 根据协议条款，罗克韦尔医疗公司将通过三年承诺（包括最低供应和采购条款）作为液体和干燥酸和碳酸氢盐浓缩物的主要供应商供应 Concerto。

2022 年 9 月，Alkem 实验室宣布，现成的细胞治疗产品 StemOne 已获得印度药品监管局 (DCGI) 的监管批准，可在印度上市。 该产品由 Alkem Laboratories 与 Stempeutics 合作推出，用于治疗膝骨关节炎，这是一种关节退行性疾病。

2022 年 3 月，Teva Pharmaceutical Industries Ltd. 的美国子公司 Teva Pharmaceuticals 推出了规格为 5 毫克、10 毫克、15 毫克和 25 毫克的 RevlimidR 1（来那度胺胶囊）的第一个仿製药。宣布在美国上市。

本报告内容

  • 区域和国家/地区细分市场份额评估
  • 向新进入者提出战略建议
  • 2020、2021、2022、2025 和 2028 年的综合市场数据
  • 市场驱动因素（市场趋势、制约因素、机遇、威胁、挑战、投资机会、建议）。
  • 根据市场预测在关键业务领域提出战略建议
  • 竞争格局映射关键共同趋势。
  • 公司简介，包括详细的战略、财务状况和近期发展
  • 映射最新技术进步的供应链趋势

免费定制优惠：

购买此报告的客户将获得以下免费定制选项之一：

  • 公司简介
    • 其他市场参与者的综合概况（最多 3 家公司）
    • 主要参与者的 SWOT 分析（最多 3 家公司）
  • 区域细分
    • 根据客户的要求对主要国家/地区的市场估计/预测/复合年增长率（注意：基于可行性检查）。
  • 竞争基准
    • 根据产品组合、区域影响力和战略联盟对主要参与者进行基准测试

内容

第 1 章执行摘要

第二章前言

  • 概览
  • 利益相关者
  • 调查范围
  • 调查方法
    • 数据挖掘
    • 数据分析
    • 数据验证
    • 研究方法
  • 调查来源
    • 主要研究来源
    • 二级研究来源
    • 假设

第三章市场趋势分析

  • 司机
  • 约束因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第 4 章波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第 5 章全球缺铁性贫血 (IDA) 治疗市场：按治疗分类

  • 母体铁疗法
  • 口服铁疗法
  • 红细胞输注疗法
  • 其他治疗

第 6 章全球缺铁性贫血 (IDA) 治疗市场：按治疗领域分类

  • 充血性心力衰竭 (CHF)
  • 肾臟科、妇产科、
  • 肿瘤学
  • 炎症性肠病
  • 其他治疗领域

第 7 章全球缺铁性贫血 (IDA) 治疗市场：按年龄分类

  • 对于老年人
  • 成人
  • 儿科

第 8 章。全球缺铁性贫血 (IDA) 治疗市场：按最终用户分类

  • 诊所
  • 医院
  • 家庭保健

第 9 章全球缺铁性贫血 (IDA) 治疗市场：按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 意大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 新西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中东和非洲
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 卡塔尔
    • 南非
    • 其他中东和非洲地区

第10章主要发展

  • 合同、伙伴关係、协作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第11章公司简介

  • Vifor Pharma Ltd
  • Teva Pharmaceutical Industries Ltd
  • Sanofi
  • Pfizer Inc
  • Novartis AG
  • Mylan N.V.
  • Lupin
  • Zydus Cadila
  • GlaxoSmithKline plc
  • Fresenius SE & Co. KGaA
  • F. Hoffmann-La Roche Ltd
  • Shield Therapeutics
  • Pharmacosmos A/S
  • AMAG Pharmaceuticals
  • Akebia Therapeutics, Inc
  • AbbVie Inc.
  • Hikma Pharmaceuticals plc
  • Alkem Laboratiories
  • Advanz Pharmaceutical
  • Rockwell Medical, Inc
Product Code: SMRC22826

According to Stratistics MRC, the Global Iron Deficiency Anemia (IDA) Therapy Market is accounted for $1.87 billion in 2022 and is expected to reach $2.36 billion by 2028 growing at a CAGR of 3.95% during the forecast period. Iron Deficiency Anemia (IDA) is a condition that occurs when there are not enough healthy red blood cells in the blood. Red blood cells, which aid in storing and transporting oxygen in the blood, are created using iron. RBCs provide oxygen to human tissues. Red blood cells contain iron, which is necessary for haemoglobin synthesis. An inadequate amount of haemoglobin may indicate that the body is not receiving enough oxygen. Foods rich in iron, such as fruits, meat, vegetables, and cereals, can be used to treat or prevent it. Consuming vitamin C can help prevent iron shortage.

According to the Global Nutrition Report, published in November 2021, it has been found that over half of Indian women aged between 15 - 49 years that is about 53% of the population are anemic.

Market Dynamics:

Driver:

Increased prevalence of iron deficiency anaemia

Iron Deficiency Anaemia (IDA) is a global health problem. It involves people of various ages and sexual orientations. However, teenage females are more susceptible to it. Increased iron need, monthly blood loss, illness, and worm infestation might be the causes. People who don't consume meat or other foods high in iron may be more susceptible to iron deficiency anaemia. Frequent blood donations and nutritional deficiencies are raising the demand for Iron Deficiency Anaemia (IDA) Therapies.

Restraint:

Lack of adequate testing

Anaemia may develop from a variety of different health issues. There aren't enough tests available to diagnose this condition. Anaemia tends to be neither properly assessed nor treated. It is commonly managed with iron supplements and recorded as a standalone diagnosis. The frequency and severity of its symptoms and indicators differ. It can cause heart failure or death if not adequately managed. These elements hinder the market demand.

Opportunity:

Growing incidence of cancer

Cancer patients are becoming more likely to have iron deficient anaemia. Lung and breast tumours have been shown to have the greatest anaemic frequency among solid tumours. Anaemia is caused by the aberrant blood cells that hematologic cancers like multiple myeloma, leukaemia, and lymphoma create. The immune system is weakened by these illnesses. Cancer treatments like chemotherapy and radiation worsen anaemia in cancer patients. These aspects create more prospects to the market.

Threat:

Side effects of iron supplements

Consuming iron-containing medications causes negative effects such as nausea, vomiting, stomach aches and constipation and issues with appetite. These medications can also cause overdose symptoms such fatigue, weakness, shallow or rapid breathing, blue skin, convulsions, pale skin, or pale fingernails. All of these adverse impacts are hampering the market expansion.

COVID-19 Impact:

The COVID-19 pandemic had a tremendous influence on the healthcare systems, with serious ramifications for both COVID-19-infected patients and non-infected patients, leading to the cancellation of treatment and procedures to manage and reserve resources. The prevalence of anaemia in COVID-19 patients resulted in a rise in the need for iron therapy and other anaemia-related treatments.

The pediatric segment is expected to be the largest during the forecast period

The pediatric segment is estimated to have a lucrative growth. Children frequently struggle with an iron shortage. It can take several forms, ranging from a minor deficit to iron deficiency anaemia. A child's growth and development might be impacted by untreated iron deficiency. Children's iron deficiencies are usually caused by inadequate nutrition, fast development, and low birth weight. Raising diagnosis of haemoglobin and hematocrit are driving the segment's demand.

The oral iron therapy segment is expected to have the highest CAGR during the forecast period

The oral iron therapy segment is anticipated to witness the fastest CAGR growth during the forecast period, due to its high iron balance restoring capacity. To replenish iron reserves and normalise ferritin levels, oral iron treatment must be used for at least three to six months. By raising the body's iron and haemoglobin levels, it alleviates the patient's symptoms. Different levels of elemental iron are included in oral iron supplements.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to its developed healthcare system. The demand for iron deficiency anaemia treatments is increasing due to the region's developed healthcare infrastructure and the presence of significant market competitors. Additionally, expanding consumer awareness of women's health issues and technical improvements are propelling market expansion in this region.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, owing to the increasing population and government initiatives. This region has huge population of women. The market demand in this area is being driven by rising healthcare costs, government initiatives to support the healthcare sector, and growing demand for IDA treatment.

Key players in the market:

Some of the key players profiled in the Iron Deficiency Anemia (IDA) Therapy Market include: Vifor Pharma Ltd, Teva Pharmaceutical Industries Ltd, Sanofi, Pfizer Inc, Novartis AG, Mylan N.V., Lupin, Zydus Cadila, GlaxoSmithKline plc, Fresenius SE & Co. KGaA, F. Hoffmann-La Roche Ltd, Shield Therapeutics, Pharmacosmos A/S, AMAG Pharmaceuticals, Akebia Therapeutics, Inc, AbbVie Inc., Hikma Pharmaceuticals plc, Alkem Laboratiories, Advanz Pharmaceutical and Rockwell Medical, Inc.

Key Developments:

In February 2023, Rockwell Medical, Inc. announced that the Company signed a three-year product purchase agreement with Concerto Renal Services ("Concerto"), the largest provider of dialysis in skilled nursing facilities in the United States. Under the terms of the agreement, Rockwell Medical will be the primary supplier of liquid and dry acid and bicarbonate concentrates to Concerto through a three-year commitment that includes supply and purchasing minimums.

In September 2022, Alkem Laboratories announced that its off-the-shelf cell therapy product, StemOne has received regulatory approval from the Drug Controller General of India (DCGI) for its launch in India. The product, launched by Alkem Laboratories in collaboration with Stempeutics, is for the treatment of Knee Osteoarthritis, a degenerative disease of the joint.

In March 2022, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced the launch of its first generic version of Revlimid®1 (lenalidomide capsules), in 5mg, 10mg, 15mg, and 25mg strengths, in the United States.

Therapies Covered:

  • Parenteral Iron Therapy
  • Oral Iron Therapy
  • Red Blood Cell Transfusion Therapy
  • Other Therapies

Therapy Areas Covered:

  • Congestive Heart Failure (CHF)
  • Renal, Obstetrics & Gynaecology
  • Oncology
  • Inflammatory Bowel Disease
  • Other Therapy Areas

Age Covered:

  • Geriatric
  • Adults
  • Pediatric

End Users Covered:

  • Clinics
  • Hospitals
  • Home Healthcare

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Iron Deficiency Anemia (IDA) Therapy Market, By Therapy

  • 5.1 Introduction
  • 5.2 Parenteral Iron Therapy
  • 5.3 Oral Iron Therapy
  • 5.4 Red Blood Cell Transfusion Therapy
  • 5.5 Other Therapies

6 Global Iron Deficiency Anemia (IDA) Therapy Market, By Therapy Area

  • 6.1 Introduction
  • 6.2 Congestive Heart Failure (CHF)
  • 6.3 Renal, Obstetrics & Gynaecology
  • 6.4 Oncology
  • 6.5 Inflammatory Bowel Disease
  • 6.6 Other Therapy Areas

7 Global Iron Deficiency Anemia (IDA) Therapy Market, By Age

  • 7.1 Introduction
  • 7.2 Geriatric
  • 7.3 Adults
  • 7.4 Pediatric

8 Global Iron Deficiency Anemia (IDA) Therapy Market, By End User

  • 8.1 Introduction
  • 8.2 Clinics
  • 8.3 Hospitals
  • 8.4 Home Healthcare

9 Global Iron Deficiency Anemia (IDA) Therapy Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Vifor Pharma Ltd
  • 11.2 Teva Pharmaceutical Industries Ltd
  • 11.3 Sanofi
  • 11.4 Pfizer Inc
  • 11.5 Novartis AG
  • 11.6 Mylan N.V.
  • 11.7 Lupin
  • 11.8 Zydus Cadila
  • 11.9 GlaxoSmithKline plc
  • 11.10 Fresenius SE & Co. KGaA
  • 11.11 F. Hoffmann-La Roche Ltd
  • 11.12 Shield Therapeutics
  • 11.13 Pharmacosmos A/S
  • 11.14 AMAG Pharmaceuticals
  • 11.15 Akebia Therapeutics, Inc
  • 11.16 AbbVie Inc.
  • 11.17 Hikma Pharmaceuticals plc
  • 11.18 Alkem Laboratiories
  • 11.19 Advanz Pharmaceutical
  • 11.20 Rockwell Medical, Inc

List of Tables

  • Table 1 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Region (2020-2028) ($MN)
  • Table 2 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy (2020-2028) ($MN)
  • Table 3 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Parenteral Iron Therapy (2020-2028) ($MN)
  • Table 4 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oral Iron Therapy (2020-2028) ($MN)
  • Table 5 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Red Blood Cell Transfusion Therapy (2020-2028) ($MN)
  • Table 6 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapies (2020-2028) ($MN)
  • Table 7 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy Area (2020-2028) ($MN)
  • Table 8 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Congestive Heart Failure (CHF) (2020-2028) ($MN)
  • Table 9 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Renal, Obstetrics & Gynaecology (2020-2028) ($MN)
  • Table 10 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oncology (2020-2028) ($MN)
  • Table 11 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Inflammatory Bowel Disease (2020-2028) ($MN)
  • Table 12 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapy Areas (2020-2028) ($MN)
  • Table 13 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Age (2020-2028) ($MN)
  • Table 14 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Geriatric (2020-2028) ($MN)
  • Table 15 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Adults (2020-2028) ($MN)
  • Table 16 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Pediatric (2020-2028) ($MN)
  • Table 17 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By End User (2020-2028) ($MN)
  • Table 18 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Clinics (2020-2028) ($MN)
  • Table 19 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Hospitals (2020-2028) ($MN)
  • Table 20 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Home Healthcare (2020-2028) ($MN)
  • Table 21 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Country (2020-2028) ($MN)
  • Table 22 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy (2020-2028) ($MN)
  • Table 23 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Parenteral Iron Therapy (2020-2028) ($MN)
  • Table 24 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oral Iron Therapy (2020-2028) ($MN)
  • Table 25 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Red Blood Cell Transfusion Therapy (2020-2028) ($MN)
  • Table 26 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapies (2020-2028) ($MN)
  • Table 27 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy Area (2020-2028) ($MN)
  • Table 28 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Congestive Heart Failure (CHF) (2020-2028) ($MN)
  • Table 29 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Renal, Obstetrics & Gynaecology (2020-2028) ($MN)
  • Table 30 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oncology (2020-2028) ($MN)
  • Table 31 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Inflammatory Bowel Disease (2020-2028) ($MN)
  • Table 32 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapy Areas (2020-2028) ($MN)
  • Table 33 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Age (2020-2028) ($MN)
  • Table 34 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Geriatric (2020-2028) ($MN)
  • Table 35 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Adults (2020-2028) ($MN)
  • Table 36 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Pediatric (2020-2028) ($MN)
  • Table 37 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By End User (2020-2028) ($MN)
  • Table 38 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Clinics (2020-2028) ($MN)
  • Table 39 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Hospitals (2020-2028) ($MN)
  • Table 40 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Home Healthcare (2020-2028) ($MN)
  • Table 41 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Country (2020-2028) ($MN)
  • Table 42 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy (2020-2028) ($MN)
  • Table 43 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Parenteral Iron Therapy (2020-2028) ($MN)
  • Table 44 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oral Iron Therapy (2020-2028) ($MN)
  • Table 45 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Red Blood Cell Transfusion Therapy (2020-2028) ($MN)
  • Table 46 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapies (2020-2028) ($MN)
  • Table 47 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy Area (2020-2028) ($MN)
  • Table 48 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Congestive Heart Failure (CHF) (2020-2028) ($MN)
  • Table 49 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Renal, Obstetrics & Gynaecology (2020-2028) ($MN)
  • Table 50 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oncology (2020-2028) ($MN)
  • Table 51 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Inflammatory Bowel Disease (2020-2028) ($MN)
  • Table 52 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapy Areas (2020-2028) ($MN)
  • Table 53 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Age (2020-2028) ($MN)
  • Table 54 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Geriatric (2020-2028) ($MN)
  • Table 55 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Adults (2020-2028) ($MN)
  • Table 56 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Pediatric (2020-2028) ($MN)
  • Table 57 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By End User (2020-2028) ($MN)
  • Table 58 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Clinics (2020-2028) ($MN)
  • Table 59 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Hospitals (2020-2028) ($MN)
  • Table 60 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Home Healthcare (2020-2028) ($MN)
  • Table 61 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Country (2020-2028) ($MN)
  • Table 62 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy (2020-2028) ($MN)
  • Table 63 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Parenteral Iron Therapy (2020-2028) ($MN)
  • Table 64 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oral Iron Therapy (2020-2028) ($MN)
  • Table 65 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Red Blood Cell Transfusion Therapy (2020-2028) ($MN)
  • Table 66 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapies (2020-2028) ($MN)
  • Table 67 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy Area (2020-2028) ($MN)
  • Table 68 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Congestive Heart Failure (CHF) (2020-2028) ($MN)
  • Table 69 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Renal, Obstetrics & Gynaecology (2020-2028) ($MN)
  • Table 70 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oncology (2020-2028) ($MN)
  • Table 71 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Inflammatory Bowel Disease (2020-2028) ($MN)
  • Table 72 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapy Areas (2020-2028) ($MN)
  • Table 73 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Age (2020-2028) ($MN)
  • Table 74 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Geriatric (2020-2028) ($MN)
  • Table 75 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Adults (2020-2028) ($MN)
  • Table 76 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Pediatric (2020-2028) ($MN)
  • Table 77 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By End User (2020-2028) ($MN)
  • Table 78 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Clinics (2020-2028) ($MN)
  • Table 79 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Hospitals (2020-2028) ($MN)
  • Table 80 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Home Healthcare (2020-2028) ($MN)
  • Table 81 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Country (2020-2028) ($MN)
  • Table 82 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy (2020-2028) ($MN)
  • Table 83 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Parenteral Iron Therapy (2020-2028) ($MN)
  • Table 84 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oral Iron Therapy (2020-2028) ($MN)
  • Table 85 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Red Blood Cell Transfusion Therapy (2020-2028) ($MN)
  • Table 86 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapies (2020-2028) ($MN)
  • Table 87 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy Area (2020-2028) ($MN)
  • Table 88 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Congestive Heart Failure (CHF) (2020-2028) ($MN)
  • Table 89 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Renal, Obstetrics & Gynaecology (2020-2028) ($MN)
  • Table 90 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oncology (2020-2028) ($MN)
  • Table 91 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Inflammatory Bowel Disease (2020-2028) ($MN)
  • Table 92 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapy Areas (2020-2028) ($MN)
  • Table 93 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Age (2020-2028) ($MN)
  • Table 94 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Geriatric (2020-2028) ($MN)
  • Table 95 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Adults (2020-2028) ($MN)
  • Table 96 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Pediatric (2020-2028) ($MN)
  • Table 97 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By End User (2020-2028) ($MN)
  • Table 98 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Clinics (2020-2028) ($MN)
  • Table 99 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Hospitals (2020-2028) ($MN)
  • Table 100 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Home Healthcare (2020-2028) ($MN)
  • Table 101 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Country (2020-2028) ($MN)
  • Table 102 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy (2020-2028) ($MN)
  • Table 103 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Parenteral Iron Therapy (2020-2028) ($MN)
  • Table 104 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oral Iron Therapy (2020-2028) ($MN)
  • Table 105 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Red Blood Cell Transfusion Therapy (2020-2028) ($MN)
  • Table 106 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapies (2020-2028) ($MN)
  • Table 107 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy Area (2020-2028) ($MN)
  • Table 108 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Congestive Heart Failure (CHF) (2020-2028) ($MN)
  • Table 109 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Renal, Obstetrics & Gynaecology (2020-2028) ($MN)
  • Table 110 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oncology (2020-2028) ($MN)
  • Table 111 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Inflammatory Bowel Disease (2020-2028) ($MN)
  • Table 112 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapy Areas (2020-2028) ($MN)
  • Table 113 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Age (2020-2028) ($MN)
  • Table 114 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Geriatric (2020-2028) ($MN)
  • Table 115 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Adults (2020-2028) ($MN)
  • Table 116 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Pediatric (2020-2028) ($MN)
  • Table 117 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By End User (2020-2028) ($MN)
  • Table 118 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Clinics (2020-2028) ($MN)
  • Table 119 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Hospitals (2020-2028) ($MN)
  • Table 120 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Home Healthcare (2020-2028) ($MN)